The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2015

Filed:

Jul. 19, 2012
Applicants:

Steffen Goletz, Glienicke, DE;

Rik J. Scheper, Amsterdam, NL;

Alan Masterson, Amsterdam, NL;

Herbert M. Pinedo, Amsterdam, NL;

Inventors:

Steffen Goletz, Glienicke, DE;

Rik J. Scheper, Amsterdam, NL;

Alan Masterson, Amsterdam, NL;

Herbert M. Pinedo, Amsterdam, NL;

Assignee:

Glycotope GmbH, Berlin, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/09 (2010.01); A61K 39/00 (2006.01); C12N 5/0784 (2010.01);
U.S. Cl.
CPC ...
C12N 5/0694 (2013.01); A61K 39/0011 (2013.01); A61K 2039/5152 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5156 (2013.01); C12N 5/0639 (2013.01); C12N 2501/15 (2013.01); C12N 2501/22 (2013.01); C12N 2501/24 (2013.01); C12N 2501/25 (2013.01); C12N 2501/39 (2013.01); C12N 2510/00 (2013.01);
Abstract

The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and test systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof.


Find Patent Forward Citations

Loading…